4^th European Biopharma Congress November 09-11, 2017 Vienna, Austria

Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.

pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy

Dr. Kang Choon Lee is Haengdan Distinguished Professor at the SungKyunKwan University (SKKU), Korea, and was director of the Center of Excellence for Future Pharmaceutical Education and Research in the College of Pharmacy at SKKU. He served as a professor and dean at the College of Pharmacy as well as the director of the Institute of Pharmaceutical Science. Prior to joining SKKU in 1992, Dr. Lee was a principal scientist at Dong-A Pharmaceutical Co. for ten years before joining Chonnam National University as a professor of pharmacy. For over 30 years, Dr. Lee’s Drug Targeting Laboratory has been focused on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs. Dr. Lee is internationally recognized as one of the leading experts in site-specific peptide/protein PEGylation and firstly demonstrated the therapeutic potential of novel site-specific PEGylated drugs such as GLP-1 and TRAIL. He has published over 150 papers in peer-reviewed journals and served as an invited speaker at many international conferences. Dr. Lee is an inventor on more than 20 patents related to specific bioconjugation and modification of peptide/protein drugs. He served as president of the Korean-American Pharmaceutical Scientists Association and vice-president of the Pharmaceutical Society of Korea and Korean Society of Pharmaceutical Science and Technology. Dr. Lee is a recipient of the Distinguished Pharmaceutical Scientist Award from the Pharmaceutical Society of Korea in 2002 and honored as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2003. He currently serves on the editorial advisory board of many international scientific journals including Pharmaceutical Research, Pharmaceutical Development and Technology, PharmSciTech, Journal of Drug Delivery and Heliyon. For clinically translating and commercializing of site-specific PEGylated peptide/protein drugs developed by his laboratory, he co-founded B&L DeliPharm, Korea and Theraly Pharmaceuticals, USA.

on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs

Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, the Parke Davis Research Institute in Fresnes, France, Ingenium Pharmaceuticals, Martinsried, Germany, and at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim manager, Dr. Mudde co-founded the biotech company f-star Biotechnology. In 2009, together with Christof Langer, he started to develop the S-TIRâ„¢ technology platform for human specific therapeutic vaccines which led to the foundation of S-TARget therapeutics GmbH in 2010, and the spin-off companies OncoQR ML GmbH (2013) and TYG oncology Ltd. (2013). Dr Mudde serves as CSO and managing director for OncoQR ML

Therapeutic vaccination with immune check point control